Compare RH & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RH | PVLA |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2011 | 2013 |
| Metric | RH | PVLA |
|---|---|---|
| Price | $133.78 | $165.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 16 |
| Target Price | $164.41 | ★ $233.80 |
| AVG Volume (30 Days) | ★ 752.4K | 248.4K |
| Earning Date | 12-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.31 | 52.62 |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,193,046,000.00 | $42,810,000.00 |
| Revenue This Year | $5.68 | N/A |
| Revenue Next Year | $9.26 | N/A |
| P/E Ratio | $57.18 | ★ N/A |
| Revenue Growth | 24.52 | ★ 65.28 |
| 52 Week Low | $106.30 | $72.23 |
| 52 Week High | $239.40 | $179.95 |
| Indicator | RH | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 50.18 | 63.60 |
| Support Level | $123.55 | $139.09 |
| Resistance Level | $137.90 | N/A |
| Average True Range (ATR) | 8.20 | 10.17 |
| MACD | -0.28 | 4.29 |
| Stochastic Oscillator | 30.36 | 76.68 |
RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and has a growing presence in hospitality with 27 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across design subcategories (RH Estates and Waterworks, for example), and has recently broadened its addressable market via expansion abroad (currently, less than 10% of sales) and its World of RH digital platform (highlighting offerings outside of home furnishings).
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.